France vs Middle East, North Africa, Afghanistan & Pakistan: Access to anti-retroviral drugs, male
France
89.0%
in 2022
Middle East, North Africa, Afghanistan & Pakistan
25.6%
in 2024
France rank
17th
Middle East, North Africa, Afghanistan & Pakistan rank
17th
Access to anti-retroviral drugs, male over time
- France
- Middle East, North Africa, Afghanistan & Pakistan
How they compare
France currently reports 89.0% against 25.6% in Middle East, North Africa, Afghanistan & Pakistan, a difference of 63.4%.
That makes France's figure about 3.5 times Middle East, North Africa, Afghanistan & Pakistan's.
Across all 23 years both countries report, France has been ahead every year.
France ranks 17th and Middle East, North Africa, Afghanistan & Pakistan ranks 17th of 141 countries.
France has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | France | Middle East, North Africa, Afghanistan & Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 79.8% | 6.1% | 73.7% | France |
| 2010s | 86.9% | 12.2% | 74.7% | France |
| 2020s | 88.7% | 20.2% | 68.5% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, France or Middle East, North Africa, Afghanistan & Pakistan?
- France, at 89.0% against 25.6% in Middle East, North Africa, Afghanistan & Pakistan as of 2022.
- What is the difference in access to anti-retroviral drugs, male between France and Middle East, North Africa, Afghanistan & Pakistan?
- 63.4%, with France ahead.
- How many years of comparable data are there for France and Middle East, North Africa, Afghanistan & Pakistan?
- 23 years are reported by both, from 2000 to 2022.
- How do France and Middle East, North Africa, Afghanistan & Pakistan rank globally for access to anti-retroviral drugs, male?
- France ranks 17th and Middle East, North Africa, Afghanistan & Pakistan ranks 17th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.